<italic style="font-style: italic">ANKK1</italic>基因多态性与非典型抗精神病药物诱导的代谢综合征的相关性研究

苗仁华; 李萌; 汪亚南; 庄星星

doi:10.6039/j.issn.1001-0408.2023.02.13

您当前的位置：

首页 >

文章列表页 >

ANKK1基因多态性与非典型抗精神病药物诱导的代谢综合征的相关性研究

药物与临床 | 更新时间：2023-02-22

- ANKK1基因多态性与非典型抗精神病药物诱导的代谢综合征的相关性研究
- Relationship between ANKK1 gene polymorphism and atypical antipsychotic drug-induced metabolic syndrome
- 中国药房 2023年34卷第2期页码：195-199
- 作者机构：
  
  安徽医科大学附属巢湖医院药剂科，安徽巢湖　238000
- 作者简介：
  
  副主任药师。研究方向：临床药学。E-mail：zzshzh@163.com
- 基金信息：
  
  安徽医科大学校科研基金项目(2020xkj222)
- DOI：10.6039/j.issn.1001-0408.2023.02.13
  中图分类号： R964;R749.3
- 纸质出版日期：2023-01-30，
  
  收稿日期：2022-06-18，
  
  修回日期：2022-11-01，
扫描看全文
苗仁华,李萌,汪亚南等.ANKK1基因多态性与非典型抗精神病药物诱导的代谢综合征的相关性研究 ^Δ[J].中国药房,2023,34(02):195-199.

MIAO Renhua,LI Meng,WANG Yanan,et al.Relationship between ANKK1 gene polymorphism and atypical antipsychotic drug-induced metabolic syndrome[J].ZHONGGUO YAOFANG,2023,34(02):195-199.
苗仁华,李萌,汪亚南等.ANKK1基因多态性与非典型抗精神病药物诱导的代谢综合征的相关性研究 ^Δ[J].中国药房,2023,34(02):195-199. DOI： 10.6039/j.issn.1001-0408.2023.02.13.

MIAO Renhua,LI Meng,WANG Yanan,et al.Relationship between ANKK1 gene polymorphism and atypical antipsychotic drug-induced metabolic syndrome[J].ZHONGGUO YAOFANG,2023,34(02):195-199. DOI： 10.6039/j.issn.1001-0408.2023.02.13.

摘要

目的

探索

ANKK1

基因rs1800497位点多态性与非典型抗精神病药物诱导的代谢综合征（MS）的相关性。

方法

纳入94例精神分裂症患者，采用微量荧光免疫法检测其

ANKK1

基因rs1800497位点分型，收集患者社会人口学信息、临床特征等数据。采用

检验比较患者性别与发生MS的相关性，基因多态性与MS发生及其危险因素的相关性。

结果

94例患者包括GG型24例（25.53%）、GA型51例（54.26%）、AA型19例（20.21%）；其中发生MS的有45例（47.87%），且男性患者的发生率显著高于女性（

＜0.05）。

ANKK1

基因rs1800497位点多态性与发生MS无相关性（

＝0.452）；但A等位基因与高血糖显著相关（

＝4.379，

＝0.036），与腹型肥胖、高血压、高TG、低HDL-C均无相关性（

＞0.05），提示A等位基因是诱发精神分裂症患者高血糖的相对危险因素[OR＝2.008，95%CI（1.039，3.881）]。

结论

ANKK1

基因rs1800497位点多态性与非典型抗精神病药物诱发MS无相关性，而携带A等位基因的精神分裂症患者发生高血糖的可能性更高，且男性患者MS发生率显著高于女性。

Abstract

OBJECTIVE

To explore the relationship between the

ANKK1

rs1800497 polymorphism and atypical antipsychotic drug-induced metabolic syndrome （MS）.

METHODS

Totally 94 patients with schizophrenia were included， and

ANKK1

rs1800497 genotypes of patients were detected by micro-fluorescence immunoassay； social demographic information， clinical characteristics and other data were collected. The

test was used to compare the correlation between the sex of patients and the occurrence of MS， and the correlation between gene polymorphism and the occurrence of MS and its risk factors.

RESULTS

Totally 94 patients included 24 cases （25.53%） of GG， 51 cases （54.26%） of GA and 19 cases of AA （20.21%）. Among them， there were 45 cases （47.87%） of MS， and the incidence of MS in male was higher than that in female （

＜0.05）. Genotype analysis showed that

ANKK1

rs1800497

polymorphism was not associated with MS （

＝0.452）.

ANKK1

rs1800497

A allele was significantly associated with hyperglycemia （

＝4.379，

＝0.036）， while it was not related to abdominal obesity， hypertension， high level of TG and low level of HDL-C （

＞0.05）， suggesting that for patients with schizophrenia， allele A was a relative risk factor for inducing hyperglycemia [OR＝2.008，95%CI（1.039， 3.881）].

CONCLUSIONS

ANKK1

rs1800497

polymorphism has no correlation with the induction of MS by atypical antipsychotics， while the schizophrenia patients with A allele are more likely to induce hyperglycemia. The incidence of MS in male patients is significantly higher than that in female patients.

关键词

锚蛋白重复和激酶域1代谢综合征基因多态性精神分裂症非典型抗精神病药物

Keywords

metabolic syndromegene polymorphismschizophreniaatypical antipsychotics

references

OWEN M J，SAWA A，MORTENSEN P B. Schizophrenia[J]. Lancet，2016，388（10039）：86-97.

MILLARD S J，BEARDEN C E，KARLSGODT K H，et al. The prediction-error hypothesis of schizophrenia：new data point to circuit-specific changes in dopamine activity[J]. Neuropsychopharmacology，2022，47（3）：628-640.

STROUP T S，GERHARD T，CRYSTAL S，et al. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia[J]. Am J Psychiatry，2016，173（2）：166-173.

CHOUINARD G，SAMAHA A N，CHOUINARD V A，et al. Antipsychotic-induced dopamine supersensitivity psychosis：pharmacology，criteria，and therapy[J]. Psychother Psychosom，2017，86（4）：189-219.

IJAZ S，BOLEA B，DAVIES S，et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia：a review of systematic reviews[J]. BMC Psychiatry，2018，18（1）：275-288.

中华医学会糖尿病学分会.中国2型糖尿病防治指南：2020年版[J].中华糖尿病杂志，2021，13（4）：315-409.

PENNINX B W J H，LANGE S M M. Metabolic syndrome in psychiatric patients：overview，mechanisms，and implications[J]. Dialogues Clin Neurosci，2018，20（1）：63-73.

NYMBERG C，BANASCHEWSKI T，BOKDE A L，et al. DRD2/ANKK1 polymorphism modulates the effect of ventral striatal activation on working memory performance[J]. Neuropsychopharmacology，2014，39（10）：2357-2365.

ALIASGHARI F，MAHDAVI R，BARATI M，et al. Genotypes of ANKK1 and DRD2 genes and risk of metabolic syndrome and its components：a cross-sectional study on Iranian women[J]. Obes Res Clin Pract，2021，15（5）：449-454.

PINTO J A F，FREITAS P H B，NUNES F D D，et al. Prevalence of polymorphisms in the ANKK1，DRD2，DRD3 genes and metabolic syndrome in refractory schizophrenia[J]. Rev Lat Am Enfermagem，2018，26：e2983.

ENGELKE R，OUANES S，GHULOUM S，et al. Proteomic analysis of plasma markers in patients maintained on antipsychotics：comparison to patients off antipsycho-tics and normal controls[J]. Front Psychiatry，2022，13：809071.

EXPERT PANEL on DETECTION，EVALUATION，and TREATMENT of HIGH BLOOD CHOLESTEROL in ADULTS. Executive summary of the third report of the national cholesterol education program（NCEP）expert panel on detection，evaluation，and treatment of high blood cholesterol in adults：Adult Treatment Panel Ⅲ[J]. JAMA，2001，285（19）：2486-2497.

中华医学会精神医学分会精神分裂症协作组.精神分裂症患者代谢综合征管理的中国专家共识[J]. 中华精神科杂志，2020，53（1）：3-10.

LUO C，LIU J，WANG X Y，et al. Pharmacogenetic correlates of antipsychotic-induced weight gain in the Chinese population[J]. Neurosci Bull，2019，35（3）：561-580.

邵青，张晓红，权伟，等. 抗精神病药物引起的不良反应回顾性分析[J]. 中国医药导报，2021，18（14）：156-159.

VANCAMPFORT D，STUBBS B，MITCHELL A J，et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders，bipolar disorder and major depressive disorder：a systematic review and meta-analysis[J]. World Psychiatry，2015，14（3）：339-347.

PAN L，YANG Z H，WU Y，et al. The prevalence，awareness，treatment and control of dyslipidemia among adults in China[J]. Atherosclerosis，2016，248（3）：2-9.

MENG Q H，LI J，CHAO Y，et al. β-estradiol adjusts intestinal function via ERβ and GPR30 mediated PI3K/Akt signaling activation to alleviate postmenopausal dyslipi-demia[J]. Biochem Pharmacol，2020，180：114134.

OISHI K，NIITSU T，KANAHARA N，et al. Genetic risks of schizophrenia identified in a matched case-control study[J]. Eur Arch Psychiatry Clin Neurosci，2021，271（4）：775-781.

ALIASGHARI F，NAZM S A，YASARI S，et al. Associations of the ANKK1 and DRD2 gene polymorphisms with overweight，obesity and hedonic hunger among women from the Northwest of Iran[J]. Eat Weight Disord，2021，26（1）：305-312.

CARDEL M I，LEMAS D J，LEE A M，et al. Taq1A polymorphism（rs1800497）is associated with obesity-related outcomes and dietary intake in a multi-ethnic sample of children[J]. Pediatr Obes，2019，14（2）：e12470.

HENI M，KULLMANN S，AHLQVIST E，et al. Interaction between the obesity-risk gene FTO and the dopamine D2 receptor gene ANKK1/Taq1A on insulin sensitivity[J]. Diabetologia，2016，59（12）：2622-2631.

MULLALLY J A，CHUNG W K，LEDUC C A，et al. Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2（rs1800497）：a pilot study[J]. Diabetes Obes Metab，2021，23（3）：850-853.

LUQUAIN-COSTAZ C，KOCKX M，ANASTASIUS M，et al. Increased ABCA1（ATP-binding cassette transporter A1）-specific cholesterol efflux capacity in schizophrenia[J]. Arterioscler Thromb Vasc Biol，2020，40（11）：2728-2737.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据

ANKK1基因多态性与非典型抗精神病药物诱导的代谢综合征的相关性研究

Relationship between ANKK1 gene polymorphism and atypical antipsychotic drug-induced metabolic syndrome

DOI：10.6039/j.issn.1001-0408.2023.02.13

摘要

Abstract

关键词

Keywords

references